Literature DB >> 21389867

Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation.

Maarten L Zandvliet1, Ellis van Liempt, Inge Jedema, Simone Kruithof, Michel G D Kester, Henk-Jan Guchelaar, J H Frederik Falkenburg, Pauline Meij.   

Abstract

Opportunistic viral infections can cause serious morbidity and mortality in immunocompromised patients after allogeneic stem cell transplantation. Clinical studies have shown that adoptive transfer of donor-derived T cells specific for cytomegalovirus (CMV), Epstein-Barr virus (EBV), or human adenovirus (HAdV) can be a safe and effective treatment of infections with these major viral pathogens. The aim of this study was to develop a method for the simultaneous isolation of coordinated CD8(+) and CD4(+) memory T-cell responses against a broad repertoire of viral epitopes. To ensure that the method was applicable to a wide variety of virus-specific T cells that may differ in phenotypic and functional properties, we focused on T cells specific for the persistent viruses, CMV and EBV, and T cells specific for HAdV and influenza (FLU), which are not repetitively activated in vivo after initial viral clearance. Following in vitro activation, nearly all T cells specific for these viruses produced interferon γ (IFN-γ) and tumor necrosis factor α, and expressed CD137, whereas the populations varied in the production of interleukin-2, degranulation, and expression of phenotypic markers. Different kinetics of IFN-γ production were observed in CMV/EBV-specific T cells and HAdV/FLU-specific T cells. However, after the stimulation of peripheral blood from seropositive donors with viral protein-spanning peptide pools, the activated virus-specific CD8(+) and CD4(+) T cells could be simultaneously isolated by either IFN-γ-based or CD137-based enrichment. This study provides an efficient and widely applicable strategy for the isolation of virus-specific T cells, which may be used for the reconstitution of virus-specific immunity in allogeneic stem cell transplantation recipients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21389867     DOI: 10.1097/CJI.0b013e318213cb90

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  16 in total

1.  Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy?

Authors:  Claus Lundegaard; Ole Lund; Morten Nielsen
Journal:  Expert Rev Vaccines       Date:  2012-01       Impact factor: 5.217

2.  A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients.

Authors:  Benjamin J D Weist; Patrizia Wehler; Linda El Ahmad; Michael Schmueck-Henneresse; Jason M Millward; Mikalai Nienen; Avidan U Neumann; Petra Reinke; Nina Babel
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

Review 3.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

Review 4.  Immunotherapy for viral and fungal infections.

Authors:  H Einsele; J Löffler; M Kapp; L Rasche; S Mielke; U G Grigoleit
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

5.  Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.

Authors:  Sanja Stevanović; Lindsey M Draper; Michelle M Langhan; Tracy E Campbell; Mei Li Kwong; John R Wunderlich; Mark E Dudley; James C Yang; Richard M Sherry; Udai S Kammula; Nicholas P Restifo; Steven A Rosenberg; Christian S Hinrichs
Journal:  J Clin Oncol       Date:  2015-03-30       Impact factor: 44.544

6.  Mesenchymal stromal cell therapy is associated with increased adenovirus-associated but not cytomegalovirus-associated mortality in children with severe acute graft-versus-host disease.

Authors:  Friso G J Calkoen; Carly Vervat; Astrid G S van Halteren; Marij J P Welters; Louise A Veltrop-Duits; Arjan C Lankester; R Maarten Egeler; Lynne M Ball; Maarten J D van Tol
Journal:  Stem Cells Transl Med       Date:  2014-06-05       Impact factor: 6.940

7.  CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.

Authors:  Qunrui Ye; De-Gang Song; Mathilde Poussin; Tori Yamamoto; Andrew Best; Chunsheng Li; George Coukos; Daniel J Powell
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

8.  The role of CD4(+) T cells in BKV-specific T cell immunity.

Authors:  B J D Weist; M Schmueck; H Fuehrer; A Sattler; P Reinke; N Babel
Journal:  Med Microbiol Immunol       Date:  2014-07-23       Impact factor: 3.402

9.  Activation-induced CD137 is a fast assay for identification and multi-parameter flow cytometric analysis of alloreactive T cells.

Authors:  N H R Litjens; E A de Wit; C C Baan; M G H Betjes
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

10.  Short-term in-vitro expansion improves monitoring and allows affordable generation of virus-specific T-cells against several viruses for a broad clinical application.

Authors:  René Geyeregger; Christine Freimüller; Stefan Stevanovic; Julia Stemberger; Gabor Mester; Jasmin Dmytrus; Thomas Lion; Hans-Georg Rammensee; Gottfried Fischer; Britta Eiz-Vesper; Anita Lawitschka; Susanne Matthes; Gerhard Fritsch
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.